Search Results - "Boggiani, D."

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer by Viansone, A., Pellegrino, B., Omarini, C., Pistelli, M., Boggiani, D., Sikokis, A., Uliana, V., Zanoni, D., Tommasi, C., Bortesi, B., Bonatti, F., Piacentini, F., Cortesi, L., Camisa, R., Sgargi, P., Michiara, M., Musolino, A.

“…HER2-positive breast cancers are rare amongst BRCA mutation carriers. No data exist regarding clinicopathological characteristics and prognosis of this…”
Get full text

EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations by Tiseo, M, Gelsomino, F, Boggiani, D, Bortesi, B, Bartolotti, M, Bozzetti, C, Sammarelli, G, Thai, E, Ardizzoni, A

“…Abstract The fusion gene EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) was recently identified as a…”
Get full text

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer by Musolino, A, Naldi, N, Dieci, M V, Zanoni, D, Rimanti, A, Boggiani, D, Sgargi, P, Generali, D G, Piacentini, F, Ambroggi, M, Cagossi, K, Gianni, L, Sarti, S, Bisagni, G, Ardizzoni, A, Conte, P F, Guarneri, V

“…Lapatinib enhances antibody-dependent cell-mediated cytotoxicity (ADCC) activity of trastuzumab. FcγR polymorphisms have been associated with both ADCC and…”
Get full text

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents by Casartelli, C., Tommasi, C., Lazzarin, A., Corianò, M., Tornali, C., Serra, O., Campanini, N., Gutiérrez-Enríquez, S., Sikokis, A., Zanoni, D., Minari, R., Bortesi, B., Michiara, M., Boggiani, D., Uliana, V., Llop-Guevara, A., Serra, V., Musolino, A., Pellegrino, B.

Get full text

Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study by Musolino, A., Falcini, F., Sikokis, A., Boggiani, D., Rimanti, A., Pellegrino, B., Silini, E.M., Campanini, N., Barbieri, E., Zamagni, C., Degli Esposti, R., Cortesi, L., Bisagni, G., Cavanna, L., Frassoldati, A., Sgargi, P., Michiara, M.

“…Although human epidermal growth factor receptor 2 (HER2) overexpression is associated with poor prognosis, patients (pts) with pT1a N0M0 breast cancers (BCs)…”
Get full text

Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) by Pellegrino, B., Cavanna, L., Boggiani, D., Zamagni, C., Frassoldati, A., Schirone, A., Caldara, A., Rocca, A., Gori, S., Piacentini, F., Berardi, R., Brandes, A.A., Foglietta, J., Villa, F., Todeschini, R., Tognetto, M., Naldi, N., Bortesi, B., Montemurro, F., Ardizzoni, A., Boni, L., Musolino, A.

“…The combination of a microtubule inhibitor (eribulin) with a nucleoside analog (gemcitabine) may synergistically induce tumor cell death, particularly in…”
Get full text

Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: A retrospective study in a sample of Italian cancer genetics clinics by Varesco, L, Viassolo, V, Viel, A, Gismondi, V, Radice, P, Montagna, M, Alducci, E, Della Puppa, L, Oliani, C, Tommasi, S, Caligo, M.A, Vivanet, C, Zuradelli, M, Mandich, P, Tibiletti, M.G, Cavalli, P, Lucci Cordisco, E, Turchetti, D, Boggiani, D, Bracci, R, Bruzzi, P, Bonelli, L

“…Abstract Purpose To evaluate in current practice the performance of BOADICEA and BRCAPRO risk models and empirical criteria based on cancer family history for…”
Get full text

145P High-risk breast cancer patients with RAD51-low tumors are characterized by good prognosis by Pellegrino, B., Llop-Guevara, A., Campanini, N., Tommasi, C., Javierre, G. Villacampa, Pedretti, F., Bortesi, B., Minari, R., Rapacchi, E., Michiara, M., Boggiani, D., Sikokis, A., Zanoni, D., Silini, E.M., Serra, V., Musolino, A.

Get full text

146P HRD/TIL-low high-risk breast cancer is characterized by good prognosis (the RADIMMUNE trial) by Pellegrino, B., Llop-Guevara, A., Solinas, C., Campanini, N., Tommasi, C., Michiara, M., Boggiani, D., Sikokis, A., Frassoldati, A., Casarini, C., Cretella, E., Zoppoli, G., Lambertini, M., Dieci, M.V., Cortesi, L., Silini, E., Balmaña, J., Willard-Gallo, K., Serra, V., Musolino, A.

Get full text

Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) by Musolino, A, Cavanna, L, Boggiani, D, Zamagni, C, Frassoldati, A, Caldara, A, Rocca, A, Gori, S, Piacentini, F, Berardi, R, Brandes, AA, Foglietta, J, Villa, F, Pellegrino, B, Todeschini, R, Tognetto, M, Naldi, N, Bortesi, B, Boni, L, Montemurro, F, Ardizzoni, A

“…Abstract Background: There are no well-established chemotherapy regimens for metastatic triple negative breast cancer. The combination of a microtubule…”
Get full text

Abstract P1-07-23: Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known screening status: Results from a multicenter population-based cancer registry study by Musolino, A, Michiara, M, Boggiani, D, Sikokis, A, Rimanti, A, Pellegrino, B, Silini, EM, Campanini, N, Barbieri, E, Sgargi, P, Falcini, F, Pinto, C

“…Abstract Introduction: Outcomes for women with pT1aN0M0 breast cancers (BC) may vary by biologic subtype. A higher proportion of HER2-positive BCs diagnosed in…”
Get full text

Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study by Musolino, A., Sikokis, A., Boggiani, D., Rimanti, A., Pellegrino, B., Silini, E.M., Campanini, N., Barbieri, E., Cortesi, L., Panebianco, M., Porzio, R., Frassoldati, A., Sgargi, P., Falcini, F., Michiara, M.

Get full text

Prognostic Impact of Interval Breast Cancer Detection in Women with pT1aN0M0 Breast Cancer with HER2-positive Status: Results from a Multicenter Population-based Cancer Registry Study by Boggiani, D., Sikokis, A., Rimanti, A., Pellegrino, B., Silini, E.M., Campanini, N., Barbieri, E., Cortesi, L., Panebianco, M., Porzio, R., Frassoldati, A., Sgargi, P., Falcini, F., Michiara, M., Musolino, A.

Get full text

Abstract P2-04-01: HER2 Status as Predictor of Mammographic Screening Detection: Comparison of Interval-and Screen-Detected Breast Cancers by Musolino, A, Michiara, M, Conti, GM, Boggiani, D, Bozzani, F, Zatelli, M, Sgargi, P, Ardizzoni, A.

“…Abstract Background: To determine whether markers of poor prognosis are associated with risk of breast cancer diagnosis in the interval between screening…”
Get full text